Literature DB >> 28742702

Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.

Ingrid G M Poodt1, Pauline E R Spronk2,3, Guusje Vugts1, Thijs van Dalen4, M T F D Vrancken Peeters5, Marjolijn L Rots4, Anne Kuijer4, Grard A P Nieuwenhuijzen1, Robert-Jan Schipper1.   

Abstract

OBJECTIVES: To evaluate patterns of care in axillary surgery for Dutch clinical T1-4N0M0 (cT1-4N0M0) breast cancer patients and to assess the effect of the American College for Surgeons Oncology Group (ACOSOG)-Z0011 and After Mapping of the Axilla: Radiotherapy Or Surgery (AMAROS) trial on axillary surgery patterns in Dutch cT1-2N0M0 sentinel node positive breast cancer patients.
BACKGROUND: Since publication of the ACOSOG-Z0011 and AMAROS trial, omitting a completion axillary lymph node dissection (cALND) in sentinel node positive breast cancer patients is proposed in selected patients.
METHODS: Data were obtained from the nationwide Nationaal Borstkanker Overleg Nederland breast cancer audit. Descriptive analyses were used to demonstrate trends in axillary surgery. Multivariable logistic regression analyses were used to identify factors associated with the omission of cALND in cT1-2N0M0 sentinel node-positive breast cancer patients.
RESULTS: Between 2011 and 2015 in cT1-4N0M0 breast cancer patients, the use of sentinel lymph node biopsy as definitive axillary staging increased from 72% to 93%, and (c)ALND as definitive axillary staging decreased from 24% to 6% (P < 0.001). The use of cALND decreased from 75% to 17% in cT1-2N0 sentinel node-positive patients (P < 0.001). Earlier year of diagnosis, lower age, primary mastectomy, invasive lobular subtype, increasing tumor grade, and treatment in a nonteaching hospital were associated with a lower probability of omitting cALND (P < 0.001).
CONCLUSIONS: This study shows a trend towards less extensive axillary surgery in Dutch cT1-T4N0M0 breast cancer patients; illustrated by an overall increase of sentinel lymph node biopsy and decrease in cALND. Despite this trend, particularly noticed in cT1-2N0 sentinel node-positive patients after publication of the ACOSOG-Z0011 and AMAROS trial, variations in patterns of care in axillary surgery are still present.

Entities:  

Mesh:

Year:  2018        PMID: 28742702     DOI: 10.1097/SLA.0000000000002440

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.

Authors:  Fabian Riedel; Jörg Heil; Manuel Feißt; Mahdi Rezai; Mareike Moderow; Christof Sohn; Florian Schütz; Michael Golatta; André Hennigs
Journal:  Breast Cancer Res Treat       Date:  2019-06-24       Impact factor: 4.872

2.  The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.

Authors:  Nina Tamirisa; Hannah V Williamson; Samantha M Thomas; Kelly E Westbrook; Rachel A Greenup; Jennifer K Plichta; Laura H Rosenberger; Terry Hyslop; Eun-Sil Shelley Hwang; Oluwadamilola M Fayanju
Journal:  J Surg Oncol       Date:  2019-05-06       Impact factor: 3.454

3.  Predicting Lymph Node Metastasis in the Era of Z0011-Necessity and Methods Remain in Question.

Authors:  Kandace P McGuire
Journal:  Eur J Breast Health       Date:  2018-04-01

4.  Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.

Authors:  Audree B Tadros; Tracy-Ann Moo; Michelle Stempel; Emily C Zabor; Atif J Khan; Monica Morrow
Journal:  Breast Cancer Res Treat       Date:  2020-01-14       Impact factor: 4.872

5.  Axillary Management in Women with Early Breast Cancer and Limited Sentinel Node Metastasis: A Systematic Review and Metaanalysis of Real-World Evidence in the Post-ACOSOG Z0011 Era.

Authors:  Tzu-Wen Huang; Chih-Ming Su; Ka-Wai Tam
Journal:  Ann Surg Oncol       Date:  2020-07-23       Impact factor: 5.344

6.  Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.

Authors:  Anita Mamtani; Emily C Zabor; Michelle Stempel; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2019-07-24       Impact factor: 5.344

7.  Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis.

Authors:  Weiqi Gao; Shuangshuang Lu; Yufei Zeng; Xiaosong Chen; Kunwei Shen
Journal:  Breast Cancer Res Treat       Date:  2022-09-08       Impact factor: 4.624

Review 8.  Addressing the problem of overtreatment in breast cancer.

Authors:  Linda M Pak; Monica Morrow
Journal:  Expert Rev Anticancer Ther       Date:  2022-05-19       Impact factor: 3.627

9.  Clinical Practice Status of Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer Patients in China: A Multicenter Study.

Authors:  Juliang Zhang; Ting Wang; Changjiao Yan; Meiling Huang; Zhimin Fan; Rui Ling
Journal:  Clin Epidemiol       Date:  2020-09-01       Impact factor: 4.790

10.  Validating the ACOSOG Z0011 Trial Result: A Population-Based Study Using the SEER Database.

Authors:  Jiwoong Jung; Byoung Hyuck Kim; Jongjin Kim; Sohee Oh; Su-Jin Kim; Chang-Sup Lim; In Sil Choi; Ki-Tae Hwang
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.